

Aldo P Maggioni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8504824/aldo-p-maggioni-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

761
papers

81,996
citations

122
h-index

275
g-index

853
ext. papers

98,264
ext. citations

8.5
avg, IF

7.32
L-index

#	Paper	IF	Citations
761	European Society of Cardiology: cardiovascular disease statistics 2021.. <i>European Heart Journal</i> , 2022 ,	9.5	22
760	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <i>European Journal of Heart Failure</i> , 2022 , 24, 143-168	12.3	7
759	Age-related changes in clinical characteristics and outcomes of chronic heart failure outpatients in a cardiology setting. A report from the Italian Network on Heart Failure. <i>International Journal of Cardiology</i> , 2022 , 346, 36-44	3.2	0
758	Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance. <i>International Journal of Cardiology</i> , 2022 , 346, 86-92	3.2	1
757	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022 , 346, 19-26	3.2	0
756	Cost-Effectiveness of Posthospital Management of Acute Coronary Syndrome: A Real-World Investigation From Italy.. <i>Value in Health</i> , 2022 , 25, 185-193	3.3	2
755	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials.. <i>Circulation: Heart Failure</i> , 2022 , CIRCULATION:HEARTFAILURE	7.6	0
754	Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry.. <i>Infection</i> , 2022 , 1	5.8	2
753	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry.. <i>European Journal of Clinical Investigation</i> , 2022 , e13773	4.6	1
752	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	6	1
751	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events.. <i>Annals of Medicine</i> , 2022 , 54, 1036-1046	1.5	1
750	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 486-495	4.6	18
749	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
748	A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	4
747	Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 790289	5.4	0
746	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2021 , 4, e2141328	10.4	8
745	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2021 ,	16.7	5

744	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6.4	0
743	Angiotensin Receptor-Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021 , 385, 1845-1855	59.2	21
742	Cancer and Infective Endocarditis: Characteristics and Prognostic Impact. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 766996	5.4	1
741	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 553	2.3	1
740	Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. <i>European Heart Journal Supplements</i> , 2021 , 23, E13-E18	1.5	2
739	Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy. <i>Advances in Therapy</i> , 2021 , 1	4.1	0
738	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007347	7.6	4
737	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <i>Clinical Drug Investigation</i> , 2021 , 41, 459-468	3.2	1
736	Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13551	4.6	2
735	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction CONTROLLED ELECTRA Registry subanalysis-Author's reply. <i>Europace</i> , 2021 , 23, 1149-1150	3.9	0
734	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. <i>European Journal of Heart Failure</i> , 2021 , 23, 906-914	12.3	28
733	Utilisation of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: Real world data from the ARIADNE registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	2
732	Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021 , 38, 341-346	4.7	2
731	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003183	5.2	2
730	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021 , 23, 1040-1048	12.3	29
729	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	15.1	7
728	Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC). <i>Heart</i> , 2021 ,	5.1	4
727	The 70/30 Rule Between Men and Women-Disparity or Opportunity?. <i>JAMA Cardiology</i> , 2021 , 6, 481-482	16.2	

726	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2
725	Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1165-1171	3.8	0
724	Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study. <i>PLoS ONE</i> , 2021 , 16, e0250931	3.7	1
723	Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC). <i>International Journal of Cardiology Congenital Heart Disease</i> , 2021 , 3, 100107	0.7	1
722	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	1
721	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021 , 143, 2129-2142	16.7	14
720	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. <i>European Journal of Internal Medicine</i> , 2021 , 89, 65-75	3.9	2
719	The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients - Heart Failure Registries of the European Society of Cardiology. <i>Kardiologia Polska</i> , 2021 , 79, 980-987	0.9	0
718	Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study. <i>Journal of Cardiovascular Computed Tomography</i> , 2021 , 15, 73-80	2.8	8
717	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 229-237	4.6	6
716	Effects of linagliptin on left ventricular Dysfunction in patients with type 2 Diabetes and concentric left ventricular geometry: results of the DYDA 2 trial. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 8-17	3.9	1
715	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021 , 23, 174-183	3.9	28
714	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 134-142	4.6	0
713	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. <i>ESC Heart Failure</i> , 2021 , 8, 95-105	3.7	4
712	Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. <i>Journal of the American Heart Association</i> , 2021 , 10, e018176	6	4
711	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. <i>Europace</i> , 2021 , 23, 49-58	3.9	2
710	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 28-33	4.6	1
709	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021 , 64, e7	6	3

708	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2021 , 22, 781-789	4.1	2
707	Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry analysis. <i>Europace</i> , 2021 , 23, 1462-1471	3.9	4
706	The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. <i>Diabetes Therapy</i> , 2021 , 12, 1445-1461	3.6	1
705	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 14-23	15.1	9
704	The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification. <i>GeroScience</i> , 2021 , 43, 2215-2229	8.9	4
703	Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. <i>European Heart Journal</i> , 2021 , 42, 4536-4549	9.5	5
702	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	9.5	13
701	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 \square phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021 , 336, 14-21	3.2	1
700	Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	3
699	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. <i>Clinical Cardiology</i> , 2021 , 44, 1333-1343	3.3	1
698	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
697	Unexpected high mortality associated with very low lipoprotein(a) after acute myocardial infarction: Identifying the unknown. <i>European Journal of Internal Medicine</i> , 2021 , 91, 26-28	3.9	
696	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	10
695	Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos. <i>JAMA Internal Medicine</i> , 2021 , 181, 1257-1258	11.5	1
694	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. <i>Journal of Agricultural and Food Chemistry</i> , 2021 , 69, 11236-11245	5.7	1
693	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021 , 144, 1380-1395	16.7	5
692	Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients. <i>Journal of Cardiovascular Computed Tomography</i> , 2021 , 15, 421-430	2.8	10
691	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1023-1031	16.2	1

690	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
689	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021 , 10, e022288	6	1
688	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. <i>American Heart Journal</i> , 2021 , 240, 73-80	4.9	0
687	One year on: The impact of COVID-19 on clinical research. <i>European Journal of Internal Medicine</i> , 2021 , 92, 24-27	3.9	0
686	Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. <i>Therapeutic Advances in Chronic Disease</i> , 2021 , 12, 20406223211026390	4.9	1
685	Maintaining the balance between benefits and risks: The example of hyperkalemia in patients with heart failure. <i>Revista Portuguesa De Cardiologia</i> , 2020 , 39, 543-544	1	
684	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 841-844	1.9	3
683	Pronóstico a largo en pacientes con insuficiencia cardiaca en España. Registro ESC-EORP-HFA Heart Failure Long-Term. <i>REC: CardioClinics</i> , 2020 , 55, 207-216	0.2	1
682	Cancer in chronic heart failure patients in the GISSI-HF trial. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13273	4.6	4
681	Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1301-1310	2.8	3
680	Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 210-216	4.6	108
679	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020 , 227, 56-63	4.9	6
678	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020 , 41, 1357-1364	9.5	20
677	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	12.3	8
676	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1675-1683	12.3	10
675	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , 2020 , 141, 1841-1854	16.7	53
674	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 1395-1407	59.2	642
673	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020 , 7, 2098-2112	3.7	14

672	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. <i>ESC Heart Failure</i> , 2020 , 7, 3288	3.7	6
671	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. <i>ESC Heart Failure</i> , 2020 , 7, 727-736	3.7	5
670	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020 , 222, 157-165	4.9	10
669	The Heart Failure Association Atlas: rationale, objectives, and methods. <i>European Journal of Heart Failure</i> , 2020 , 22, 638-645	12.3	13
668	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. <i>Diabetes Care</i> , 2020 , 43, 843-851	14.6	12
667	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. <i>European Journal of Internal Medicine</i> , 2020 , 74, 55-60 ^{3.9}	3.9	6
666	European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 7-9	4.6	18
665	Understanding the use of observational and randomized data in cardiovascular medicine. <i>European Heart Journal</i> , 2020 , 41, 2571-2578	9.5	13
664	The battle against COVID-19: mortality in Italy. <i>European Heart Journal</i> , 2020 , 41, 2050-2052	9.5	17
663	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 906-910	12.3	2
662	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1378-1389	12.3	32
661	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1424-1437	12.3	13
660	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. <i>International Journal of Cardiology</i> , 2020 , 313, 89-96	3.2	0
659	Key words to be adopted for COVID-19 research. <i>European Heart Journal</i> , 2020 , 41, 4229-4230	9.5	2
658	Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. <i>Cardiac Failure Review</i> , 2020 , 6, e28	4.2	5
657	Maintaining the balance between benefits and risks: The example of hyperkalemia in patients with heart failure. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020 , 39, 543-544	0	
656	In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. <i>Cardiology Journal</i> , 2020 , 27, 25-37	1.4	4
655	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020 , 42, e59-e64	1.7	2

654	Prevalence Of familial hypercholesterolaemia (FH) in Italian Patients with coronary artery disease: The POSTER study. <i>Atherosclerosis</i> , 2020 , 308, 32-38	3.1	3
653	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020 , 26, 932-943	3.3	2
652	Measuring multimorbidity inequality across Italy through the multisource comorbidity score: a nationwide study. <i>European Journal of Public Health</i> , 2020 , 30, 916-921	2.1	7
651	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 313-323	0.7	4
650	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 92-102	12.3	35
649	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 315-329	12.3	16
648	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. <i>American Heart Journal</i> , 2020 , 222, 93-104	4.9	0
647	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020 , 43, 643-652	14.6	19
646	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
645	PCSK9 Inhibitors New Users: Analysis of Prescription Patterns and Patients Characteristics from an Italian Real-world Study. <i>Clinical Drug Investigation</i> , 2020 , 40, 173-181	3.2	11
644	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020 , 41, 12-85	9.5	330
643	Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. <i>Europace</i> , 2020 , 22, 558-566	3.9	4
642	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020 , 43, 446-452	14.6	31
641	Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. <i>American Heart Journal</i> , 2020 , 220, 12-19	4.9	16
640	Integration of care for reaching targets in Diabetic patients: Design of the INSIDE Study. <i>Diabetes Therapy</i> , 2020 , 11, 359-367	3.6	2
639	Hiperpotasemia en pacientes con insuficiencia cardiaca en España y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 313-323	1.5	10
638	COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. <i>International Journal of Cardiology</i> , 2020 , 318, 160-164	3.2	2
637	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 175	8.7	1

636	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. <i>Drugs and Aging</i> , 2020 , 37, 925-933	4.7	12
635	ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. <i>ESC Heart Failure</i> , 2020 , 7, 3013-3021	3.7	3
634	Adapting to survive. <i>European Heart Journal</i> , 2020 , 41, 3981-3983	9.5	
633	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 ,	4.6	15
632	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa registry subanalysis. <i>Europace</i> , 2020 , 22, 1718-1728	3.9	6
631	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
630	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020 , 41, 3787-3797	9.5	35
629	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. <i>Circulation</i> , 2020 , 142, 1725-1735	16.7	27
628	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2020 , 7, 3601	3.7	6
627	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 296-307	3.9	17
626	The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 100-104	4.6	5
625	Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 1704-1717	8.4	32
624	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020 , 22, 1698-1707	12.3	6
623	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320912497	3.9	24
622	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320908698	3.9	25
621	Pregnancy outcomes in women with aortic coarctation. <i>Heart</i> , 2020 ,	5.1	8
620	Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. <i>Europace</i> , 2019 , 21, 1802-1808	3.9	5
619	Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. <i>European Heart Journal</i> , 2019 , 40, 3222-3232	9.5	169

618	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
617	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019 , 140, 1451-1459	16.7	22
616	Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. <i>Circulation</i> , 2019 , 140, 1156-1169	16.7	82
615	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
614	EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. <i>European Heart Journal</i> , 2019 , 40, 2745-2749	9.5	25
613	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019 , 393, 407-415	40	300
612	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72
611	Audits of clinical practice should be encouraged. Use of loop diuretics in patients without a diagnosis of heart failure should be discouraged. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 289-290	3.9	1
610	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3296-3302	5.6	8
609	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019 , 140, 529-537	16.7	50
608	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019 , 21, 1383-1397	12.3	20
607	Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 1338-1352	12.3	62
606	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019 , 285, 135-146	3.1	106
605	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019 , 21, 1013-1022	3.9	28
604	Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). <i>European Heart Journal</i> , 2019 , 40, 3848-3855	9.5	97
603	The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 202-207	4.6	26
602	Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTrolled) Registry. <i>Europace</i> , 2019 , 21, 1096-1105	3.9	4
601	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 824-835	3.9	288

600	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 273-286	16.2	65
599	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. <i>Europace</i> , 2019 , 21, 230-238	3.9	13
598	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
597	Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1661-1662	12.3	2
596	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
595	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019 , 157, 682-691.e2	13.3	181
594	Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019 , 42, 1365-1373	1.6	10
593	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019 , 157, 403-412.e5	13.3	62
592	Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry. <i>Europace</i> , 2019 , 21, 1876-1889	3.9	2
591	Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTrolled ELECTRa registry: is female sex a predictor of complications?. <i>Europace</i> , 2019 , 21, 1890-1899	3.9	1
590	Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries. <i>Polish Archives of Internal Medicine</i> , 2019 , 129, 106-116	1.9	3
589	Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 Trial). Rationale, Design, and Baseline Characteristics of the Study Population. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 547-555	3.9	3
588	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019 , 381, 2497-2505	59.2	861
587	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 1586-1595	12.3	12
586	Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry. <i>ESC Heart Failure</i> , 2019 , 6, 1167-1177	3.7	2
585	Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 660-663	3.9	2
584	The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 527-535	4.3	3
583	Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU. <i>European Journal of Heart Failure</i> , 2019 , 21, 322-333	12.3	16

582	Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry. <i>Europace</i> , 2019 , 21, 771-780	3.9	25
581	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019 , 208, 100-109	1.6	5
580	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019 , 42, 313-320	1.6	7
579	Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 77-86	3.9	5
578	Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 334-342	4.6	8
577	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. <i>European Journal of Heart Failure</i> , 2019 , 21, 208-217	12.3	33
576	Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) Registry Sub-Analysis. <i>Europace</i> , 2019 , 21, 645-654	3.9	20
575	Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: Data from a large database in a community setting. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 836-846	3.9	10
574	Background and design of the ACCA-EAPCI registry on ST-segment elevation myocardial infarction of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 63-67	4.3	3
573	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264
572	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-895	12.3	65
571	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. <i>Atherosclerosis</i> , 2018 , 271, 120-127	3.1	22
570	Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 172-179	6.4	24
569	Lugano perspectives: final considerations. <i>European Heart Journal Supplements</i> , 2018 , 20, C25-C26	1.5	
568	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. <i>Metabolism: Clinical and Experimental</i> , 2018 , 83, 205-215	12.7	20
567	Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018 , 20, 747-757	3.9	81
566	Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. <i>European Heart Journal</i> , 2018 , 39, 1481-1495	9.5	106
565	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 377-387	3.9	8

564	Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 254, 136-141	3.2	6
563	East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. <i>European Journal of Heart Failure</i> , 2018 , 20, 1071-1075	12.3	11
562	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2018 , 29, 566-572	2.7	16
561	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 105-113	18.1	336
560	Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. <i>International Journal of Cardiology</i> , 2018 , 265, 162-168	3.2	20
559	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. <i>European Heart Journal</i> , 2018 , 39, 1784-1793	9.5	60
558	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. <i>European Journal of Cancer</i> , 2018 , 94, 126-137	7.5	98
557	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. <i>Clinical Research in Cardiology</i> , 2018 , 107, 214-221	6.1	21
556	Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease. <i>Heart</i> , 2018 , 104, 745-752	5.1	9
555	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 268-277	12.3	25
554	A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. <i>International Journal of Cardiology</i> , 2018 , 250, 215-222	3.2	3
553	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 281-291	12.3	17
552	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 332-341	12.3	49
551	Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 100-110	12.3	49
550	Expert consensus document: A diamond approach to personalized treatment of angina. <i>Nature Reviews Cardiology</i> , 2018 , 15, 120-132	14.8	66
549	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. <i>European Journal of Heart Failure</i> , 2018 , 20, 345-354	12.3	49
548	Risk of heart failure in diabetic patients receiving sulfonyleureas. <i>European Journal of Heart Failure</i> , 2018 , 20, 1371-1372	12.3	1
547	Dose-dependent efficacy of Eb blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 273, 141-146	3.2	10

546	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
545	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018 , 271, 68-74	3.2	23
544	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 255-260	3	4
543	Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 4030-4039	9.5	12
542	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018 , 20, F1-F74 ¹⁻⁵	1.5	17
541	Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 281-286	3.9	6
540	Effect of β -blockers on 1-year survival and hospitalizations in patients with heart failure and atrial fibrillation: results from ESC-HF Pilot and ESC-HF Long-Term Registry. <i>Polish Archives of Internal Medicine</i> , 2018 , 128, 649-657	1.9	3
539	Impact of digoxin on risk of death in heart failure patients treated with β -blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. <i>Kardiologia Polska</i> , 2018 , 76, 1064-1072	0.9	4
538	The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. <i>Kardiologia Polska</i> , 2018 , 76, 1336-1343	0.9	11
537	Heart failure patients with a previous coronary revascularization: results from the ESC-HF Registry. <i>Kardiologia Polska</i> , 2018 , 76, 144-152	0.9	0
536	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 677-686	12.3	13
535	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204
534	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
533	CardioScope mapping the cardiovascular funding landscape in Europe. <i>European Heart Journal</i> , 2018 , 39, 2423-2430	9.5	4
532	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1631263	3.9	13
531	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1760-1763	12.3	2
530	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e009304	6	12
529	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2018 , 25, e475-e486	1	6

528	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018 , 39, 4277-4284	9.5	102
527	Reply: The Barcelona Bio-HF Calculator: A Contemporary Web-Based Heart Failure Risk Score. <i>JACC: Heart Failure</i> , 2018 , 6, 810-811	7.9	0
526	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018 , 6, 452-462	7.9	51
525	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). <i>American Journal of Cardiology</i> , 2018 , 122, 578-583	3	8
524	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018 , 55, 28-34	3.9	37
523	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. <i>European Heart Journal</i> , 2017 , 38, 1303-1316	9.5	112
522	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. <i>European Journal of Heart Failure</i> , 2017 , 19, 1121-1141	12.3	114
521	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. <i>Journal of the American Medical Association</i> , 2017 , 317, 1681-1690	4.9	49
520	Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. <i>International Journal of Cardiology</i> , 2017 , 246, 62-67	3.2	7
519	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. <i>Diabetes Care</i> , 2017 , 40, 671-678	14.6	65
518	Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries). <i>American Journal of Cardiology</i> , 2017 , 119, 2021-2029	3	11
517	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 376, 1956-1964	59.2	185
516	Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. <i>Journal of Cardiovascular Medicine</i> , 2017 , 18, 144-151	1.9	5
515	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1242-1254	12.3	166
514	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017 , 103, 1156-1162	5.1	8
513	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 552-562	12.3	19
512	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017 , 38, 1632-1637	9.5	15
511	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heArT failure patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017 , 19, 782-791	12.3	54

510	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035	3.8	97
509	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2606-2618	15.1	47
508	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45
507	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heArT failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017 , 38, 1119-1127	9.5	192
506	The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. <i>European Heart Journal</i> , 2017 , 38, 2995-3005	9.5	190
505	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017 , 241, 450-456	3.2	24
504	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1574-1585	12.3	301
503	Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF. <i>American Heart Journal</i> , 2017 , 188, 189-195	4.9	5
502	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017 , 187, 1-9	4.9	39
501	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 1527-1539	59.2	390
500	The year in cardiology 2016: heart failure. <i>European Heart Journal</i> , 2017 , 38, 705-711	9.5	1
499	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. <i>Europace</i> , 2017 , 19, 1439-1448	2.8	34
498	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	16.7	5
497	Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure. <i>Circulation Journal</i> , 2017 , 81, 1543-1546	2.9	
496	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017 , 19, 535-543	3.9	26
495	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17058	51.1	87
494	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
493	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1217-1227	59.2	562

492	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 887-897	18.1	154
491	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 1228-1239	59.2	1017
490	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. <i>International Journal of Cardiology</i> , 2017 , 248, 166-172	3.2	6
489	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EMPLOYED antithrombotic therapies in patients with acute coronary syndromes hospitalized in Italian cardiac care units Registry. <i>Journal of Cardiovascular Medicine</i> , 2017 , 18, 580-589	1.9	5
488	Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	13
487	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	7.9	176
486	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 41-51	59.2	232
485	Uncovering difference: a glimpse at patients with heart failure in low-income and middle-income countries. <i>The Lancet Global Health</i> , 2017 , 5, e634-e635	13.6	1
484	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	39
483	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 54-65	12.3	92
482	Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 201-208	12.3	90
481	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2017 , 19, 271-279	12.3	22
480	Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study. <i>Acta Diabetologica</i> , 2017 , 54, 123-131	3.9	14
479	Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 673-681	12.3	28
478	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. <i>Journal of Cardiac Failure</i> , 2017 , 23, 2-9	3.3	12
477	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. <i>Cardiology</i> , 2017 , 136, 128-137	1.6	27
476	The European Society of Cardiology ACCA-EAPCI Registry on ST elevation myocardial infarction. <i>European Heart Journal</i> , 2017 , 38, 138-139	9.5	2
475	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017 , 19, D3-D54	1.5	11

474	Real-world Atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2017 , 19, 722-733	3.9	49
473	Epidemiology of Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017 , 243, 15-33	3.2	40
472	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016 , 37, 152-60	9.5	21
471	Validity and reliability of the HeartQoL questionnaire in a large sample of stable coronary patients: The EUROASPIRE IV Study of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 714-21	3.9	27
470	Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016 , 109, 377-382	2.7	24
469	Therapeutic Strategies and Health Costs of Patients Admitted for a Cardiovascular Event in Italy. <i>Global & Regional Health Technology Assessment</i> , 2016 , 3, GRHTA.5000221	0.2	3
468	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>American Heart Journal</i> , 2016 , 181, 83-91	4.9	22
467	Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016 , 18, 1119-28	12.3	103
466	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016 , 37, 2105-14	9.5	184
465	The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. <i>European Journal of Heart Failure</i> , 2016 , 18, 402-10	12.3	70
464	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016 , 1, 93-100	5.6	
463	Coronary atherosclerosis in outlier subjects at the opposite extremes of traditional risk factors: Rationale and preliminary results of the Coronary Atherosclerosis in outlier subjects: Protective and novel Individual Risk factors Evaluation (CAPIRE) study. <i>American Heart Journal</i> , 2016 , 173, 18-26	4.9	10
462	Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 365-374	15.1	106
461	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016 , 174, 103-10	4.9	70
460	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1144-50	3	16
459	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. <i>Europace</i> , 2016 , 18, 191-200	3.9	11
458	Usefulness of High-Sensitivity Cardiac Troponin T for the Identification of Outlier Patients With Diffuse Coronary Atherosclerosis and Low-Risk Factors. <i>American Journal of Cardiology</i> , 2016 , 117, 1397-404	3.4	12
457	The use of HeartQoL in patients with coronary heart disease: Association with risk factors and European reference values. The EUROASPIRE IV study of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1174-86	3.9	9

456	Real-world management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. <i>Europace</i> , 2016 , 18, 648-57	3.9	45
455	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 611-616	3	11
454	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). <i>Diabetes Care</i> , 2016 , 39, 709-16	14.6	48
453	Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. <i>International Journal of Cardiology</i> , 2016 , 203, 587-93	3.2	27
452	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. <i>European Heart Journal</i> , 2016 , 37, 164-73	9.5	42
451	Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. <i>Kardiologia Polska</i> , 2016 , 74, 251-61	0.9	13
450	Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis. <i>Patient Preference and Adherence</i> , 2016 , 10, 523-30	2.4	8
449	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016 , 18, 613-25	12.3	316
448	Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016 , 18, 523-33	12.3	74
447	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016 , 18, 859-68	12.3	26
446	Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart Failure Long-Term Registry). <i>American Journal of Cardiology</i> , 2016 , 118, 535-42	3	12
445	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016 , 6, 30271	4.9	35
444	Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. <i>International Journal of Cardiology</i> , 2016 , 209, 153-60	3.2	33
443	Risk of Pregnancy in Moderate and Severe Aortic Stenosis: From the Multinational ROPAC Registry. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1727-1737	15.1	68
442	Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016 , 220, 131-6	3.2	30
441	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	14
440	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 441-52	4.3	66
439	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 168-78	6.4	19

438	Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers. <i>Circulation: Heart Failure</i> , 2015 , 8, 428-37	7.6	20
437	Pregnancy in Women With a Mechanical Heart Valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). <i>Circulation</i> , 2015 , 132, 132-42	16.7	196
436	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015 , 17, 224-32	12.3	62
435	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015 , 17, 434-41	12.3	29
434	Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial. <i>International Journal of Cardiology</i> , 2015 , 178, 85-90	3.2	14
433	Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. <i>International Journal of Obesity</i> , 2015 , 39, 849-57	5.5	5
432	Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 1548-56	3.9	29
431	Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015 , 17, 570-82	12.3	54
430	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation</i> , 2015 , 131, 1486-94; discussion 1494	16.7	66
429	Granulocyte-colony stimulating factor for large anterior ST-elevation myocardial infarction: rationale and design of the prospective randomized phase III STEM-AMI OUTCOME trial. <i>American Heart Journal</i> , 2015 , 170, 652-658.e7	4.9	9
428	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. <i>Europace</i> , 2015 , 17, 1777-86	3.9	103
427	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015 , 132, 2297-304	16.7	49
426	Epidemiology of Heart Failure in Europe. <i>Heart Failure Clinics</i> , 2015 , 11, 625-35	3.3	51
425	Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country. <i>European Journal of Health Economics</i> , 2015 , 16, 909-11	3.6	
424	A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. <i>Heart Rhythm</i> , 2015 , 12, 2069-77	6.7	52
423	Rationale and design of GISSI OUTLIERS VAR Study in bicuspid aortic valve patients: prospective longitudinal, multicenter study to investigate correlation between surgical, echo distinctive features, histologic and genetic findings in phenotypically homogeneous outlier cases. <i>International Journal of Cardiology</i> , 2015 , 199, 180-5	3.2	3
422	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
421	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials". <i>Circulation</i> , 2015 , 132, e358	16.7	1

420	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2251-62	27.4	188
419	Short- and long-term mortality and hospital readmissions among patients with new hospitalization for heart failure: A population-based investigation from Italy. <i>International Journal of Cardiology</i> , 2015 , 181, 81-7	3.2	31
418	Cost of poor adherence to anti-hypertensive therapy in five European countries. <i>European Journal of Health Economics</i> , 2015 , 16, 65-72	3.6	48
417	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. <i>Europace</i> , 2015 , 17, 24-31	3.9	113
416	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015 , 385, 351-61	4.0	409
415	Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). <i>JACC: Clinical Electrophysiology</i> , 2015 , 1, 326-334	4.6	37
414	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 591-600	12.3	52
413	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015 , 17, 544-58	12.3	236
412	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. <i>European Journal of Heart Failure</i> , 2015 , 17, 1114-23	12.3	39
411	The 30-day metric in acute heart failure revisited: data from IN-HF Outcome, an Italian nationwide cardiology registry. <i>European Journal of Heart Failure</i> , 2015 , 17, 1032-41	12.3	19
410	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 1022-31	12.3	40
409	Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) - Polish population. <i>Archives of Medical Science</i> , 2015 , 11, 743-50	2.9	6
408	EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology. <i>European Heart Journal Cardiovascular Imaging</i> , 2015 , 16, 466-70	4.1	29
407	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015 , 36, 1106-14	9.5	37
406	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. <i>European Heart Journal</i> , 2015 , 36, 1958-65	9.5	75
405	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
404	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6 ³		28
403	Clinical characteristics and management of hospitalized and ambulatory patients with heart failure--results from ESC heart failure long-term registry-Egyptian cohort. <i>ESC Heart Failure</i> , 2015 , 2, 159-167	3.7	24

402	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. <i>Value in Health</i> , 2015 , 18, 1098-104	3.3	8
401	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 551-561	3.9	10
400	Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. <i>American Journal of Medicine</i> , 2015 , 128, 509-18.e2	2.4	166
399	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 98-108	12.3	23
398	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015 , 17, 194-206	3.9	30
397	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. <i>Lancet, The</i> , 2015 , 385, 1397-405	4.0	756
396	Hospital readmissions of patients with heart failure: the impact of hospital and primary care organizational factors in Northern Italy. <i>PLoS ONE</i> , 2015 , 10, e0127796	3.7	20
395	The Economic Crisis and Acute Myocardial Infarction: New Evidence Using Hospital-Level Data. <i>PLoS ONE</i> , 2015 , 10, e0142810	3.7	6
394	Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?. <i>Arrhythmia and Electrophysiology Review</i> , 2015 , 4, 163-8	3.2	5
393	Use and misuse of statins after ACS: analysis of a prescription database of a community setting of 2,042,968 subjects. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 1109-16	3.9	6
392	Real-world Antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. <i>American Journal of Medicine</i> , 2014 , 127, 519-29.e1	2.4	123
391	Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. <i>European Journal of Heart Failure</i> , 2014 , 16, 103-11	12.3	239
390	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014 , 16, 308-19	3.9	224
389	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1713-21	3	35
388	Cardiac medication during pregnancy, data from the ROPAC. <i>International Journal of Cardiology</i> , 2014 , 177, 124-8	3.2	64
387	The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014 , 176, 1249-51	3.2	3
386	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 401-8	7.6	27
385	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014 , 35, 2797-815	9.5	231

384	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 743-50	3	8
383	The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. <i>European Heart Journal</i> , 2014 , 35, 1466-78	9.5	141
382	Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 778-85	15.1	168
381	Newest additions to heart failure treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1849-61	4	1
380	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. <i>International Journal of Cardiology</i> , 2014 , 172, 588-94	3.2	63
379	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 135.e1-135.e81	1.5	9
378	Overweight, obesity, and outcomes: fat mass and beyond. <i>Lancet, The</i> , 2014 , 383, 935-6	4.0	31
377	Impact of renal dysfunction on the Seattle Heart Failure Model. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 163-9	5.8	4
376	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. <i>International Journal of Cardiology</i> , 2014 , 173, 163-9	3.2	76
375	Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 1-10	4.3	14
374	Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 1056-65	5.8	21
373	Ten years differences in recently onset atrial fibrillation and flutter incidence and management. <i>Monaldi Archives for Chest Disease</i> , 2014 , 82, 153-9	2.7	4
372	The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. <i>International Journal of Obesity</i> , 2014 , 38, 1110-4	5.5	123
371	Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). <i>European Heart Journal</i> , 2014 , 35, 3365-76	9.5	161
370	Rationale and design of the SOLuble guanylate Cyclase stimulatOR in heArT failurE Studies (SOCRATES). <i>European Journal of Heart Failure</i> , 2014 , 16, 1026-38	12.3	97
369	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. <i>European Journal of Heart Failure</i> , 2014 , 16, 583-91	12.3	80
368	Burden of new hospitalization for heart failure: a population-based investigation from Italy. <i>European Journal of Heart Failure</i> , 2014 , 16, 729-36	12.3	58
367	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1006-15	27.4	285

366	Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 1090-6	3.9	5
365	Predictors of mortality in acute heart failure and severe renal dysfunction. Does formula for glomerular filtration rate have any impact? Data from IN-HF outcome registry. <i>International Journal of Cardiology</i> , 2014 , 172, e96-7	3.2	2
364	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. <i>Journal of Invasive Cardiology</i> , 2014 , 26, 563-9	0.7	23
363	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. <i>BMC Cardiovascular Disorders</i> , 2013 , 13, 28	2.3	33
362	Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study. <i>European Journal of Internal Medicine</i> , 2013 , 24, 324-32	3.9	15
361	Outcomes, health costs and use of antiplatelet agents in 7,082 patients admitted for an acute coronary syndrome occurring in a large community setting. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 333-40	3.9	5
360	Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. <i>Diabetes Research and Clinical Practice</i> , 2013 , 101, 236-42	7.4	12
359	Wine consumption and risk of cardiovascular events after myocardial infarction: results from the GISSI-Prevenzione trial. <i>International Journal of Cardiology</i> , 2013 , 163, 282-287	3.2	31
358	Should we revise our approach to optimal medical therapy? The case of chronic heart failure. <i>European Heart Journal</i> , 2013 , 34, 2792-4	9.5	9
357	Tubular damage and worsening renal function in chronic heart failure. <i>JACC: Heart Failure</i> , 2013 , 1, 417-24	9	73
356	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013 , 18, 107-22	5	39
355	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013 , 15, 947-59	12.3	63
354	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013 , 166, 629-35	4.9	21
353	ELECTRa (European Lead Extraction ConTRolled) Registry--shedding light on transvenous lead extraction real-world practice in Europe. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2013 , 24, 171-5	0.8	18
352	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , 2013 , 168, 3691-7	3.2	19
351	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2013 , 15, 747-55	12.3	9
350	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013 , 15, 679-89	12.3	26
349	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 61-8	12.3	15

348	Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 820-9	15.1	85
347	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013 , 167, 1677-87	3.2	82
346	Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram. <i>Circulation: Heart Failure</i> , 2013 , 6, 31-9	7.6	75
345	Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review. <i>Clinical Research in Cardiology</i> , 2013 , 102, 1-10	6.1	3
344	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , 2013 , 1, 488-96	7.9	49
343	Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. <i>American Heart Journal</i> , 2013 , 165, 216-25	4.9	66
342	Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013 , 166, 935-40.e1	4.9	27
341	Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. <i>International Journal of Cardiology</i> , 2013 , 167, 2893-903	3.3	54
340	n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 1289-95	12.3	25
339	Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. <i>International Journal of Cardiology</i> , 2013 , 167, 262-9	3.2	30
338	Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 571-9	15.1	47
337	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). <i>International Journal of Cardiology</i> , 2013 , 168, 2416-22	3.2	9
336	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. <i>Heart Rhythm</i> , 2013 , 10, 226-32	6.7	19
335	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 53.e1-53.e46	1.5	17
334	Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. <i>American Heart Journal</i> , 2013 , 165, 208-15.e4	4.9	51
333	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013 , 112, 1763-9	3	6
332	Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1240-9	15.1	216
331	Prevalence and prognostic role of anaemia in patients with acute heart failure and preserved or depressed ventricular function. <i>Internal and Emergency Medicine</i> , 2013 , 8, 147-55	3.7	16

330	Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , 2013 , 368, 1210-9	59.2	331
329	Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. <i>Journal of Cardiac Failure</i> , 2013 , 19, 390-7	3.3	100
328	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1125-35	27.4	248
327	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2013 , 34, 2949-3003	9.5	3076
326	Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>European Heart Journal</i> , 2013 , 34, 835-43	9.5	276
325	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Heart Journal</i> , 2013 , 34, 3117-27	9.5	47
324	Cardiovascular biomarkers, cardiac dysfunction, and outcomes in patients with type 2 diabetes: a prospective, multicenter study. <i>Diabetes Care</i> , 2013 , 36, e137-8	14.6	3
323	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013 , 34, 1404-13	9.5	595
322	Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of AntiThrombotic Agents: the MANTRA registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 27-34	4.3	22
321	Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. <i>Circulation: Heart Failure</i> , 2013 , 6, 473-81	7.6	131
320	Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 1228-35	12.3	46
319	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013 , 15, 1173-84	12.3	388
318	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 1401-11	12.3	100
317	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013 , 15, 1082-94	12.3	143
316	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013 , 15, 334-41	12.3	20
315	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 194-202	12.3	126
314	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013 , 15, 808-17	12.3	462
313	Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 1382-9	12.3	18

312	Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. <i>European Heart Journal</i> , 2013 , 34, 657-65	9.5	293
311	Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2013 , 6, 47-52	7.6	56
310	Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients: beneficial effects on autonomic modulation of heart rate. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 296-300	1.9	12
309	Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. <i>PLoS ONE</i> , 2013 , 8, e59121	3.7	40
308	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. <i>EuroIntervention</i> , 2013 , 8, 1362-71	3.1	142
307	In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. <i>Journal of Invasive Cardiology</i> , 2013 , 25, 170-6	0.7	6
306	Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. <i>European Journal of Heart Failure</i> , 2012 , 14, 185-92	12.3	33
305	Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , 2012 , 14, 1208-17	12.3	93
304	A review of the epidemiological profile of patients with atrial fibrillation and heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 1133-40	2.5	8
303	Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study). <i>Acute Cardiac Care</i> , 2012 , 14, 71-80		20
302	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
301	Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: data from the IN-CHF Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012 , 22, 442-8	4.5	11
300	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2	659
299	The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , 2012 , 18, 515-23	3.3	51
298	Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 750-8	7.6	62
297	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. <i>BMC Cardiovascular Disorders</i> , 2012 , 12, 85	2.3	15
296	Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. <i>American Heart Journal</i> , 2012 , 164, 884-92.e2	4.9	20
295	Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2012 , 110, 1657-62	3	9

294	Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). <i>American Journal of Cardiology</i> , 2012 , 110, 1803-8	3	6
293	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012 , 22, 997-1006	4.5	36
292	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 938.e1-938.e59	1.5	27
291	Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. <i>Diabetologia</i> , 2012 , 55, 2348-55	10.3	49
290	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
289	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 131-143	3.9	9
288	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. <i>Heart Failure Reviews</i> , 2012 , 17, 485-509	5	79
287	Comparison of late results of percutaneous coronary intervention among stable patients ≤ 5 versus >65 years of age with an occluded infarct related artery (from the Occluded Artery Trial). <i>American Journal of Cardiology</i> , 2012 , 109, 614-9	3	2
286	The management of acute myocardial infarction in the cardiological intensive care units in Italy: the BLITZ 4 Quality Campaign for performance measurement and quality improvement. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012 , 1, 143-52	4.3	30
285	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1767-817	9.5	3691
284	Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 935-43	3.9	22
283	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012 , 14, 1056-66	12.3	88
282	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
281	Targeting myocardial substrate metabolism in heart failure: potential for new therapies. <i>European Journal of Heart Failure</i> , 2012 , 14, 120-9	12.3	107
280	Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. <i>European Journal of Heart Failure</i> , 2012 , 14, 302-11	12.3	126
279	Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2012 , 14, 992-9	12.3	72
278	Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. <i>Circulation</i> , 2012 , 125, 280-8	16.7	177
277	Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. <i>Circulation</i> , 2012 , 126, 2402-7	16.7	47

276	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012 , 33, 2782-95	9.5	121
275	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. <i>Europace</i> , 2012 , 14, 1094-103	3.9	97
274	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012 , 33, 1750-7	9.5	508
273	Transcatheter Valve Treatment Pilot Registry: design and current status. <i>European Heart Journal</i> , 2012 , 33, 2243-5	9.5	0
272	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. <i>Europace</i> , 2012 , 14, 666-74	3.9	79
271	Elderly patients with acute coronary syndromes admitted to Italian intensive cardiac care units: a Blitz-3 Registry sub-analysis. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 165-74	1.9	7
270	Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?. <i>Journal of Hypertension</i> , 2012 , 30, 647-54	1.9	13
269	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 415-22	1.9	26
268	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
267	Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. <i>American Heart Journal</i> , 2011 , 161, 333-342	4.9	47
266	Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. <i>American Heart Journal</i> , 2011 , 161, 1067-72	4.9	29
265	Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. <i>American Heart Journal</i> , 2011 , 161, 1012-23.e3	4.9	13
264	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. <i>American Heart Journal</i> , 2011 , 161, 1156-62	4.9	10
263	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , 2011 , 162, 382-9	4.9	24
262	Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011 , 162, 613-619.e1	4.9	69
261	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
260	Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 783-91	4.5	19
259	Role of renin-angiotensin system inhibitors in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 374; author reply 375	1.9	

258	Relation between serum sodium levels and prognosis in outpatients with chronic heart failure: neutral effect of treatment with beta-blockers and angiotensin-converting enzyme inhibitors: data from the Italian Network on Congestive Heart Failure (IN-CHF database). <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 723-31	1.9	17
257	Adiponectin in chronic heart failure: influence of diabetes and genetic variants. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 1330-8	4.6	13
256	Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. <i>Journal of Internal Medicine</i> , 2011 , 269, 160-71	10.8	55
255	Opposing effects of beta-blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. <i>American Journal of Cardiology</i> , 2011 , 107, 1705-9	3	14
254	Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 315-21	3.9	5
253	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011 , 13, 755-64	12.3	15
252	Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. <i>European Journal of Heart Failure</i> , 2011 , 13, 148-53	12.3	56
251	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. <i>European Journal of Heart Failure</i> , 2011 , 13, 1253-60	12.3	27
250	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. <i>European Heart Journal</i> , 2011 , 32, 2563-72	9.5	99
249	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). <i>European Journal of Heart Failure</i> , 2011 , 13, 100-6	12.3	60
248	Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011 , 13, 746-54	12.3	25
247	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 415-23		25
246	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011 , 32, 1227-34	9.5	114
245	Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. <i>Circulation</i> , 2011 , 124, 2320-8	16.7	26
244	Clinical outcome of renal tubular damage in chronic heart failure. <i>European Heart Journal</i> , 2011 , 32, 2705-12	9.5	149
243	Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy. <i>Circulation: Cardiovascular Imaging</i> , 2011 , 4, 721-8	3.9	7
242	Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome. <i>Journal of Evaluation in Clinical Practice</i> , 2010 , 16, 82-91	2.5	8
241	Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. <i>Obesity</i> , 2010 , 18, 987-94	8	13

240	Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 26-34	6.7	14
239	Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. <i>Circulation</i> , 2010 , 122, 597-602	16.7	148
238	Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. <i>Circulation: Heart Failure</i> , 2010 , 3, 65-72	7.6	81
237	Evidence for the efficacy of ARBs across the cardiovascular continuum. <i>Current Medical Research and Opinion</i> , 2010 , 26, 1203-18	2.5	12
236	The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010 , 12, 1229-37	12.3	37
235	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010 , 12, 557-65	12.3	51
234	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010 , 12, 1076-84	12.3	258
233	Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 1345-53	12.3	62
232	Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 367-74	12.3	56
231	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. <i>Heart</i> , 2010 , 96, 838-42	5.1	22
230	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 338-47	12.3	116
229	Age-dependent prognostic significance of atrial fibrillation in outpatients with chronic heart failure: data from the Italian Network on Congestive Heart Failure Registry. <i>Cardiology</i> , 2010 , 116, 79-88 ^{1.6}	1.6	11
228	The role of cardiac registries in evidence-based medicine. <i>European Heart Journal</i> , 2010 , 31, 525-9	9.5	96
227	Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2010 , 16, 964-70	3.3	48
226	Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , 2010 , 159, 857-63	4.9	18
225	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial INfarcTION Trial (VALIANT). <i>American Heart Journal</i> , 2010 , 160, 145-51	4.9	32
224	Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. <i>American Heart Journal</i> , 2010 , 160, 286-93	4.9	52
223	Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. <i>New England Journal of Medicine</i> , 2010 , 363, 905-17	59.2	627

222	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010 , 375, 735-42	40	1644
221	Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. <i>Heart</i> , 2010 , 96, 1909-14	5.1	25
220	Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. <i>Circulation: Heart Failure</i> , 2010 , 3, 314-25	7.6	120
219	Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. <i>American Journal of Therapeutics</i> , 2010 , 17, e78-87	1	16
218	Epidemiology and patterns of care of patients admitted to Italian Intensive Cardiac Care units: the BLITZ-3 registry. <i>Journal of Cardiovascular Medicine</i> , 2010 , 11, 450-61	1.9	32
217	Evolution of renal function during and after an episode of cardiac decompensation: results from the Italian survey on acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2010 , 11, 234-43	1.9	16
216	Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. <i>Clinical Cardiology</i> , 2010 , 33, 536-41	3.3	12
215	Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. <i>Trials</i> , 2010 , 11, 79	2.8	36
214	Heart Failure Pilot protocol. <i>European Heart Journal</i> , 2010 , 31, 2184-6	9.5	1
213	Prescription at discharge of recommended treatments for secondary prevention in patients with ST-segment elevation myocardial infarction according to reperfusion strategies. Results from the IN-ACS outcome study. <i>Acute Cardiac Care</i> , 2009 , 11, 222-8		4
212	Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. <i>Circulation</i> , 2009 , 120, 835-42	16.7	165
211	Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. <i>Circulation: Heart Failure</i> , 2009 , 2, 209-16	7.6	43
210	Valsartan for prevention of recurrent atrial fibrillation. <i>New England Journal of Medicine</i> , 2009 , 360, 1606-12	9.7	367
209	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009 , 30, 2226-32	9.5	72
208	Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. <i>European Heart Journal</i> , 2009 , 30, 1666-73	9.5	55
207	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>European Heart Journal</i> , 2009 , 30, 2327-36	9.5	84
206	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial infarction trial (VALIANT). <i>European Heart Journal</i> , 2009 , 30, 1450-6	9.5	40
205	SCOUT trial reports on the safety profile of sibutramine in patients with cardiovascular diseases. <i>Physician and Sportsmedicine</i> , 2009 , 37, 95-7	2.4	1

204	Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. <i>European Journal of Heart Failure</i> , 2009 , 11, 68-76	12.3	78
203	Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. <i>European Journal of Heart Failure</i> , 2009 , 11, 77-84	12.3	15
202	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , 2009 , 11, 795-801	12.3	88
201	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. <i>Heart</i> , 2009 , 95, 1920-4	5.1	23
200	Heart rate in coronary syndromes and heart failure. <i>Progress in Cardiovascular Diseases</i> , 2009 , 52, 38-45	8.5	34
199	Where are we with the management of hypertension? From science to clinical practice. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 66-73	2.3	12
198	Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009 , 26, 469-87	4.1	13
197	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 735-48	2.5	32
196	Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , 2009 , 15, 747-55	3.3	8
195	Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. <i>American Heart Journal</i> , 2009 , 157, 957-70	4.9	43
194	Clinical characteristics, management, and prognosis of octogenarians with acute heart failure admitted to cardiology wards: results from the Italian Survey on Acute Heart Failure. <i>American Heart Journal</i> , 2009 , 158, 126-32	4.9	22
193	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet, The</i> , 2009 , 374, 525-33	4.0	302
192	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009 , 11, 292-8	12.3	77
191	A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. <i>Journal of Cardiovascular Medicine</i> , 2009 , 10, 200-3	1.9	7
190	Clinical implications and management of bleeding events in patients with acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2009 , 10, 677-86	1.9	7
189	Effects of tolvaptan on dyspnoea relief from the EVEREST trials. <i>European Heart Journal</i> , 2009 , 30, 2233-40	4.9	58
188	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. <i>European Heart Journal</i> , 2009 , 30, 56-65	9.5	94
187	Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). <i>EuroIntervention</i> , 2009 , 5, 610-8	3.1	6

186	Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. <i>American Journal of Cardiology</i> , 2008 , 101, 457-61	3	18
185	Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. <i>American Journal of Cardiology</i> , 2008 , 101, 925-9	3	19
184	Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1640-8	15.1	141
183	Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. <i>American Heart Journal</i> , 2008 , 155, 388-94	4.9	21
182	High-risk myocardial infarction in the young: the VALSartan In Acute myocardial infarction (VALIANT) trial. <i>American Heart Journal</i> , 2008 , 155, 706-11	4.9	21
181	Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). <i>American Journal of Cardiology</i> , 2008 , 101, 607-12	3	158
180	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. <i>Lancet, The</i> , 2008 , 372, 547-53	4.0	1179
179	Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 1223-30	4.0	998
178	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 1231-9	4.0	767
177	Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. <i>Archives of Internal Medicine</i> , 2008 , 168, 2194-204		258
176	Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2656-66	27.4	128
175	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. <i>European Heart Journal</i> , 2008 , 29, 748-56	9.5	76
174	Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. <i>Europace</i> , 2008 , 10, 403-11	3.9	144
173	Depression worsens outcomes in elderly patients with heart failure: an analysis of 48,117 patients in a community setting. <i>European Journal of Heart Failure</i> , 2008 , 10, 714-21	12.3	40
172	Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. <i>Hypertension</i> , 2008 , 51, 48-54	8.5	53
171	Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. <i>Circulation: Heart Failure</i> , 2008 , 1, 17-24	7.6	292
170	Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. <i>Journal of Cardiovascular Pharmacology</i> , 2008 , 52, 393-402	3.1	18
169	Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: data from the BLITZ study. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 1045-51	1.9	5

168	Cardiogenic shock developing in the coronary care unit in patients with ST-elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 1023-9	1.9	16
167	The role of thrombolysis in acute ischemic stroke. <i>Herz</i> , 2008 , 33, 498-506	2.6	4
166	Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 627-34	2.8	44
165	Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. <i>JACC: Cardiovascular Interventions</i> , 2008 , 1, 511-20	5	11
164	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. <i>Vascular Health and Risk Management</i> , 2008 , 4, 223-34	4.4	9
163	Management of Chronic Heart Failure Therapy in the Setting of Acute Heart Failure 2008 , 533-544		
162	Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. <i>Circulation</i> , 2007 , 116, 1242-9	16.7	533
161	Prediction of mode of death in heart failure: the Seattle Heart Failure Model. <i>Circulation</i> , 2007 , 116, 392-6.7	16.7	218
160	Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)-Prevenzione trial. <i>Circulation</i> , 2007 , 116, 2944-51	16.7	50
159	Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. <i>European Journal of Heart Failure</i> , 2007 , 9, 397-402	12.3	59
158	FDA and CPMP rulings on subgroup analyses. <i>Cardiology</i> , 2007 , 107, 97-102	1.6	25
157	Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. <i>European Heart Journal</i> , 2007 , 28, 2915-23	9.5	109
156	Left bundle branch block as a risk factor for progression to heart failure. <i>European Journal of Heart Failure</i> , 2007 , 9, 7-14	12.3	112
155	Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1319-31	27.4	1118
154	Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1332-43	27.4	625
153	Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. <i>Journal of Cardiovascular Medicine</i> , 2007 , 8 Suppl 1, S34-7	1.9	26
152	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). <i>Journal of Cardiovascular Medicine</i> , 2007 , 8, 683-91	1.9	15
151	Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. <i>American Journal of Hypertension</i> , 2007 , 20, 997-1004	2.3	29

150	Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. <i>Journal of Cardiac Failure</i> , 2007 , 13, 797-804	3.3	66
149	Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , 2007 , 119, 48-53	3.2	57
148	Importancia de los ácidos grasos omega-3 en la prevención secundaria del infarto agudo de miocardio. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006 , 6, 62D-71D	0.2	
147	Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. <i>European Heart Journal</i> , 2006 , 27, 393-405	9.5	46
146	Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study. <i>European Journal of Heart Failure</i> , 2006 , 8, 649-57	12.3	24
145	Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2006 , 8, 591-8	12.3	92
144	The Seattle Heart Failure Model: prediction of survival in heart failure. <i>Circulation</i> , 2006 , 113, 1424-33	16.7	1394
143	What is the optimal reperfusion strategy for elderly patients with acute MI?. <i>The American Journal of Geriatric Cardiology</i> , 2006 , 15, 14-8		
142	The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>Journal of the American College of Cardiology</i> , 2006 , 47, 726-33	15.1	120
141	Coronary intervention for persistent occlusion after myocardial infarction. <i>New England Journal of Medicine</i> , 2006 , 355, 2395-407	59.2	505
140	Use of valsartan in post-myocardial infarction and heart failure patients. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7 Suppl 1, S19-22	3	1
139	Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. <i>American Journal of Medicine</i> , 2006 , 119, 70.e23-30	2.4	82
138	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006 , 151, 985-91	4.9	218
137	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. <i>American Heart Journal</i> , 2006 , 151, 754.e7-754.e17	4.9	21
136	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2006 , 152, 500-8	4.9	7
135	High pulse pressure and low mean arterial pressure: two predictors of death after a myocardial infarction. <i>Journal of Hypertension</i> , 2006 , 24, 2377-85	1.9	24
134	Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. <i>Journal of Cardiovascular Medicine</i> , 2006 , 7, 29-38	1.9	37
133	Efficacy of Angiotensin receptor blockers in cardiovascular disease. <i>Cardiovascular Drugs and Therapy</i> , 2006 , 20, 295-308	3.9	20

132	Nationwide survey on acute heart failure in cardiology ward services in Italy. <i>European Heart Journal</i> , 2006 , 27, 1207-15	9.5	171
131	Angiotensin II antagonists in acute and post-acute myocardial infarction 2006 , 1-12		
130	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2005 , 26, 2114-9	9.5	24
129	Review of the new ESC guidelines for the pharmacological management of chronic heart failure. <i>Country Review Ukraine</i> , 2005 , 7, J15-J20		1
128	VALIANT (VALsartan In Acute myocardial INfarcTION) trial. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 507-12	4	20
127	Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). <i>American Heart Journal</i> , 2005 , 149, 548-57	4.9	341
126	Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. <i>American Journal of Hypertension</i> , 2005 , 18, 1288-93	2.3	40
125	Determinantes de insuficiencia cardíaca tardía postinfarto de miocardio: resultados del estudio GISSI Prevenzione. <i>Revista Espanola De Cardiologia</i> , 2005 , 58, 1266-1272	1.5	7
124	Determinants of Late-Onset Heart Failure in Myocardial Infarction Survivors: GISSI Prevenzione Trial Results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005 , 58, 1266-1272	0.7	
123	Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. <i>Journal of Cardiac Failure</i> , 2005 , 11, 91-8	3.3	100
122	Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999. <i>Journal of Cardiac Failure</i> , 2005 , 11, 270-8	3.3	28
121	Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). <i>Journal of Cardiac Failure</i> , 2005 , 11, 260-9	3.3	154
120	Metabolic syndrome and risk of cardiovascular events after myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 277-83	15.1	122
119	Left ventricular assessment in myocardial infarction: the VALIANT registry. <i>Archives of Internal Medicine</i> , 2005 , 165, 2162-9		15
118	Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. <i>American Journal of Cardiology</i> , 2005 , 96, 698-704	3	58
117	Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. <i>Circulation</i> , 2005 , 112, 1121-7	16.7	195
116	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. <i>European Journal of Heart Failure</i> , 2005 , 7, 904-9	12.3	90
115	Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. <i>New England Journal of Medicine</i> , 2005 , 352, 2581-8	59.2	588

114	Does eplerenone benefit postinfarction patients with heart failure and left ventricular systolic dysfunction?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 618-9		
113	Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. <i>European Journal of Heart Failure</i> , 2005 , 7, 710-21	12.3	94
112	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005 , 83, 98-103	2.4	13
111	Global Secondary Prevention strategiEs to Limit event recurrence after myocardial infarction: the GOSPEL study. A trial from the Italian Cardiac Rehabilitation Network: rationale and design. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005 , 12, 555-561		11
110	Clinical characteristics and outcome of diabetic patients with acute myocardial infarction. Data from the BLITZ-1 study. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005 , 6, 374-83		9
109	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004 , 25, 1454-70	9.5	176
108	Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. <i>Circulation</i> , 2004 , 110, 2349-54	16.7	358
107	Expert consensus document on beta-adrenergic receptor blockers. <i>European Heart Journal</i> , 2004 , 25, 1341-62	9.5	365
106	N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. <i>Circulation</i> , 2004 , 110, 128-34	16.7	242
105	Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. <i>European Journal of Heart Failure</i> , 2004 , 6, 937-45	12.3	74
104	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. <i>European Heart Journal</i> , 2004 , 25, 292-9	9.5	262
103	The MealNwoman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists. <i>European Journal of Heart Failure</i> , 2004 , 6, 769-79	12.3	34
102	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , 2004 , 6, 635-41	12.3	180
101	Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). <i>American Journal of Cardiology</i> , 2004 , 93, 1156-9	3	23
100	RAAS inhibitors in the cardiovascular continuum: what is still missing?. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 311-20	3.9	2
99	Valsartan for the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 181-93	4	4
98	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2004 , 25, 1911-9	9.5	98
97	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 1213-1232	1.5	1

96	Doppler-derived mitral deceleration time as a strong prognostic marker of left ventricular remodeling and survival after acute myocardial infarction: results of the GISSI-3 echo substudy. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1646-53	15.1	117
95	Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. <i>New England Journal of Medicine</i> , 2004 , 351, 1285-95	59.2	1464
94	Trial finds candesartan reduces cardiovascular deaths and hospital admissions in people with heart failure, but may not affect all cause mortality. <i>Evidence-based Cardiovascular Medicine</i> , 2004 , 8, 94-5; discussion 96-7, 98-100		
93	Participation versus education: the GISSI story and beyond. <i>American Heart Journal</i> , 2004 , 148, 222-9	4.9	13
92	The long pentraxin PTX3: from innate immunity to ischemic heart disorders. <i>International Congress Series</i> , 2004 , 1262, 63-66		
91	In-hospital and one-year outcomes of patients with high-risk acute myocardial infarction treated with thrombolysis or primary coronary angioplasty. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2004 , 5, 136-45		3
90	VALSartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. <i>European Journal of Heart Failure</i> , 2003 , 5, 537-44	12.3	58
89	Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT. <i>European Heart Journal</i> , 2003 , 24, 613-22	9.5	15
88	Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. <i>European Heart Journal</i> , 2003 , 24, 1616-29	9.5	93
87	Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. <i>European Heart Journal</i> , 2003 , 24, 1727-34	9.5	42
86	Prescription patterns of diuretics in chronic heart failure: a contemporary background as a clue to their role in treatment. <i>Journal of Cardiac Failure</i> , 2003 , 9, 210-8	3.3	23
85	Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. <i>Journal of Cardiac Failure</i> , 2003 , 9, 192-202	3.3	42
84	Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAM) trial. <i>American Heart Journal</i> , 2003 , 146, 133	4.9	6
83	Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds--the TEMISTOCLE study. <i>American Heart Journal</i> , 2003 , 146, E12	4.9	78
82	Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>New England Journal of Medicine</i> , 2003 , 349, 1893-906	59.2	1892
81	Ergometric score systems after myocardial infarction: prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction. <i>American Heart Journal</i> , 2003 , 145, 475-83	4.9	15
80	Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. <i>British Heart Journal</i> , 2003 , 89, 299-305		67
79	Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , 2003 , 107, 1278-83	16.7	698

78	Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003 , 4, 479-83		1
77	Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003 , 4, 607-13		12
76	Impact of diabetes on the current in-hospital management of heart failure. From the TEMISTOCLE study. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003 , 4, 685-94		2
75	Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002 , 40, 761-3	5.9	57
74	Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , 2002 , 106, 2454-8	16.7	259
73	Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. <i>Circulation</i> , 2002 , 105, 1897-903	16.7	1059
72	Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. <i>Hypertension</i> , 2002 , 40, 470-6	8.5	130
71	Clinical value of 12-lead electrocardiography to predict the long-term prognosis of GISSI-1 patients. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1594-600	15.1	22
70	Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1414-21	15.1	271
69	The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?. <i>Blood Pressure</i> , 2002 , 11, 328-38	1.7	9
68	Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). <i>American Heart Journal</i> , 2002 , 143, 45-55	4.9	138
67	Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. <i>American Heart Journal</i> , 2002 , 143, 398-405	4.9	569
66	Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2002 , 3, 587-92		9
65	Debate: Should statin be used in patients with heart failure?. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 266-267		10
64	Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). <i>American Journal of Cardiology</i> , 2001 , 88, 382-7	3	108
63	Cardiac protection by pharmacological modulation of inflammation. <i>Expert Opinion on Investigational Drugs</i> , 2001 , 10, 1913-24	5.9	2
62	Heart Failure: Treatment strategies for heart failure: beta blockers and antiarrhythmics. <i>British Heart Journal</i> , 2001 , 85, 97-103		3
61	Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1829-35	15.1	279

60	Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. <i>American Heart Journal</i> , 2001 , 141, 131-8	4.9	83
59	Absence of slowest oscillations in short term heart rate variability of post-myocardial infarction patients. GISSI-3 arrhythmias substudy. GISSI-3 Arrhythmias Substudy Investigators. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2001 , 90, 127-31	2.4	3
58	Spectral and bidirectional filters give different results for signal-averaged ECG analysis in patients with postmyocardial infarction. GISSI-3 Arrhythmias Substudy Investigators. <i>Journal of Electrocardiology</i> , 2000 , 33, 233-40	1.4	2
57	The role of myocardial viability in deriving benefit from reestablishing infarct-related artery flow after acute myocardial infarction. <i>Progress in Cardiovascular Diseases</i> , 2000 , 42, 455-470	8.5	10
56	Comparison of one-year outcome in women versus men with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2000 , 86, 353-7	3	55
55	Secondary prevention: improving outcomes following myocardial infarction. <i>British Heart Journal</i> , 2000 , 84 Suppl 1, i5-7:discussion i50		2
54	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 2000 , 139, 609-17	4.9	97
53	Epidemiologic study of use of resources in patients with unstable angina: the EARISA registry. On behalf on the EARISA Investigators (Epidemiologia dell'Assorbimento di Risorse nell'Ischemia, Scompenso e Angina). <i>American Heart Journal</i> , 2000 , 140, 253-63	4.9	12
52	Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. <i>American Heart Journal</i> , 2000 , 140, 727-50	4.9	142
51	PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. <i>Circulation</i> , 2000 , 102, 636-41	16.7	345
50	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1801-7	15.1	129
49	Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 127-35	15.1	39
48	The Heart in Diabetes: Results of Trials 2000 , 55-65		
47	Electrocardiographic patterns in acute inferior myocardial infarction with and without right ventricle involvement: classification, diagnostic and prognostic value, masking effect. <i>Clinical Cardiology</i> , 1999 , 22, 37-44	3.3	16
46	Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. <i>American Heart Journal</i> , 1999 , 138, 247-53	4.9	116
45	How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI. <i>American Heart Journal</i> , 1999 , 138, S183-7	4.9	8
44	Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. GISSI-2 Investigators. Grupo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. <i>American Heart Journal</i> , 1999 , 137, 443-52	4.9	49
43	Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. <i>American Journal of Cardiology</i> , 1998 , 81, 822-7	3	112

42	Very early administration of ACE-inhibitors in acute myocardial infarction. <i>International Journal of Cardiology</i> , 1998 , 65 Suppl 1, S61-4	3.2	1
41	Ramipril following acute MI attenuated LV remodeling. <i>Evidence-based Cardiovascular Medicine</i> , 1998 , 2, 13		1
40	Within-patient variability of hormone and cytokine concentrations in heart failure. <i>Pharmacological Research</i> , 1998 , 37, 213-7	10.2	25
39	Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. <i>Pharmacoeconomics</i> , 1998 , 13, 337-46	4.4	11
38	Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: the GISSI-3 database. <i>American Heart Journal</i> , 1998 , 135, 443-8	4.9	4
37	Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators. <i>Circulation</i> , 1998 , 98, 2659-65	16.7	133
36	A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. <i>New England Journal of Medicine</i> , 1998 , 338, 8-14	59.2	229
35	The Heart in Diabetes: Results of Trials 1998 , 51-60		
34	Treatment of acute myocardial infarction today. <i>American Heart Journal</i> , 1997 , 134, S9-14	4.9	2
33	Elevated cardiac troponin T levels were associated with increased 30-day mortality in patients presenting with acute myocardial ischemia. <i>Evidence-based Cardiovascular Medicine</i> , 1997 , 1, 39-40		
32	The GISSI Story (1983-1996): A Comprehensive Review. <i>Journal of Interventional Cardiology</i> , 1997 , 10, 3-28	1.8	3
31	Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value. <i>Clinical Cardiology</i> , 1997 , 20, 327-31	3.3	12
30	Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. <i>Circulation</i> , 1997 , 96, 4239-45	16.7	149
29	Factors influencing the non-administration of thrombolytic therapy in 17944 patients randomized to GISSI-3 trial. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 246	15.1	2
28	Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. <i>Journal of Hypertension</i> , 1996 , 14, 743-50	1.9	39
27	Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. <i>Cardiology</i> , 1996 , 87 Suppl 1, 16-22	1.6	3
26	Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience). <i>American Journal of Cardiology</i> , 1996 , 78, 153-7	3	5
25	Reproducibility of wall motion score and its correlation with left ventricular ejection fraction in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 1996 , 78, 855-8	3	21

24	Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase. The Calcium Antagonist in Reperfusion Study (CARES) Group. <i>American Journal of Cardiology</i> , 1996 , 78, 1049-52	3	13
23	Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. <i>Circulation</i> , 1996 , 94, 432-6	16.7	167
22	ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. <i>Circulation</i> , 1995 , 92, 3132-7	16.7	140
21	A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis. <i>Journal of the American College of Cardiology</i> , 1994 , 24, 608-15	15.1	85
20	Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) Data Base. <i>Journal of the American College of Cardiology</i> , 1994 , 24, 608-15	15.1	38
19	Frequency of predischarge ventricular arrhythmias in postmyocardial infarction patients depends on residual left ventricular pump performance and is independent of the occurrence of acute reperfusion. The GISSI-2 Investigators. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 290-5	15.1	5
18	Ethical committees and noninformed consent. <i>Journal of the American College of Cardiology</i> , 1994 , 24, 1178	15.1	
17	Cytokines in Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1994 , 23, 1-6	3.1	61
16	Cytokines in Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1994 , 23, 1	3.1	127
15	Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 1788-94	15.1	206
14	Comparison of frequency, diagnostic and prognostic significance of pericardial involvement in acute myocardial infarction treated with and without thrombolytics. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). <i>American Journal of Cardiology</i> , 1993 , 71, 1377-81	3	50
13	The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. <i>New England Journal of Medicine</i> , 1992 , 327, 1-6	59.2	274
12	GISSI Trials in Acute Myocardial Infarction. <i>Chest</i> , 1990 , 97, 146S-150S	5.3	3
11	The Ideal Thrombolytic Agent: GISSI-2 and ISIS-3. <i>Journal of Interventional Cardiology</i> , 1990 , 3, 157-168	1.8	
10	The case of GISSI in changing the attitudes and practice of Italian cardiologists. <i>Statistics in Medicine</i> , 1990 , 9, 17-26; discussion 26-7	2.3	22
9	Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status. <i>Clinical Pharmacokinetics</i> , 1990 , 18, 91-103	6.2	9
8	One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. The GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico) investigators. <i>American Journal of Cardiology</i> , 1989 , 63, 1174-8	3	73
7	Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias. <i>Clinical Pharmacokinetics</i> , 1988 , 14, 187-8	6.2	11

6	Amiodarone and desethylamiodarone: plasma concentrations, therapeutic effects and side effects. <i>Journal of the American College of Cardiology</i> , 1988 , 11, 209-10	15.1	4
5	In-hospital prognosis of patients with acute myocardial infarction complicated by primary ventricular fibrillation. <i>New England Journal of Medicine</i> , 1987 , 317, 257-61	59.2	101
4	Cardiac amyloidosis involving the conduction system and the aortocoronary neuroreceptors. Clinicopathologic correlates. <i>Chest</i> , 1986 , 90, 619-21	5.3	12
3	Two false-negative responses to the ajmaline test in the Wolff-Parkinson-White syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1985 , 8, 832-7	1.6	2
2	Incessant atrioventricular nodal reciprocating tachycardia successfully treated with intravenous amiodarone. <i>American Heart Journal</i> , 1985 , 110, 159-61	4.9	2
1	Amiodarone distribution in human tissues after sudden death during Holter recording. <i>American Journal of Cardiology</i> , 1983 , 52, 217-8	3	30